Reports
Reports
Sale
The global Holter ECG market size was valued at USD 543.3 million in 2023, driven by the increasing prevalence of cardiovascular diseases across the globe. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 to achieve a value of USD 1053.9 million by 2032.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Holter ECG is an ambulatory electrocardiography device that records the heart rhythms of a patient for at least 24 hours. It is portable, consists of adhesive electrodes that are attached to the chest, and offers an accurate diagnosis of any cardiac condition over several days.
The rising demand for 12-lead Holter ECG is driving the market growth of Holter ECG. The inclination towards 12-lead Holter ECG over traditional Holter ECG displaying two or three leads is due to the offering of vector information and its efficiency in diagnosing arrhythmias and localisation of myocardial ischemia, which is bolstering the market development of Holter ECG. In addition, they play a critical role in evaluating the effect of drugs or interventional therapeutic procedures in patients with heart failure and permanent atrial fibrillation, which is leading Holter ECG market growth.
Also, they offer information for risk stratification with the automatic analysis of parameters in 12-lead Holter ECG and are very accurate in the diagnosis of supraventricular tachycardia (SVT), ventricular tachycardia (VT), atrial flutter, atrial fibrillation, and monomorphic or Polymorphic VTs, thus invigorating the market growth. The efforts taken by market players in developing 12-lead Holter ECG with active electrodes, battery life, and that are compatible with T-shirts are likely to aid the market for Holter ECG over the forecast period.
The increasing prevalence of cardiovascular diseases and the mortality rates associated with them are contributing to the steady market growth of Holter ECG. The importance of Holter ECG in assisting doctors in diagnosing and providing accurate treatment for critical cardiac conditions by continuously monitoring the heart rhythms of a patient is providing impetus to market development. In addition, the rising preference for Holter ECG due to its portability and non-interference with the routine activities of the patients is contributing the Holter ECG market share. The reduced availability of medical staff is also contributing to the market expansion of personal healthcare systems such as Holter ECG.
Moreover, the Holter ECG plays a critical role in eliminating the need for extended stays at hospitals, offers better patient recovery in home environments, and is also cost-effective. The government initiatives in developing such long-term monitoring solutions for accurate diagnosis and reducing cardiovascular diseases among the population are propelling the market for Holter ECG. Further, the investments made in the development of Holter ECGs with extended recording and episode detection are expected to aid the Holter ECG market growth over the forecast period.
Prominent FDA Approvals
In May 2023, Abbott’s Assert-IQ™ insertable cardiac monitor (ICM) received U.S. Food and Drug Administration (FDA) clearance, providing physicians with a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. This clearance builds on Abbott's portfolio of connected health devices that can better help doctors manage and treat their patients remotely.
ICM's small devices contain sensors that are inserted just under the skin of the chest. These devices are designed to monitor a person's heart constantly and in real time. Using Bluetooth® technology, Abbott's Assert-IQ ICM is designed to remain connected to a transmitter, usually the person's cell phone where it checks heart rhythms every 20 seconds, transmitting results in real-time to the clinic's portal.
The market for Holter ECG is expected to grow significantly with the development of a low-cost Holter monitor that is wireless and equipped with AI-assisted diagnostics. This innovative device promises quick and accurate cardiac screening, which plays a significant role in underprivileged areas where cardiovascular death rates are rising. By providing accessible and innovative healthcare solutions, this device has the potential to boost global Holter ECG market growth.
Additionally, in Jan 2024, iRhythm Technologies received European approval for its latest Zio wearable cardiac monitor, designed to detect irregular heartbeats such as atrial fibrillation. The new model is made compact, thinner, and lighter compared to the previous Zio XT ECG-recording patch. According to iRhythm, cases of arrhythmia and stroke have been on the rise in Europe, creating a sense of urgency for improved detection. The CE mark’s green light covers both the 14-day Zio wearable monitor and its artificial intelligence-powered ECG analysis software, dubbed ZEUS.
The approval for the Zio wearable cardiac monitor in Europe which is also addressing the increasing cases of arrhythmia and stroke may result in Holter ECG market growth. The smaller design and advanced AI analysis offer improved detection, meeting the rising demand for enhanced cardiac monitoring solutions.
Research Activities Poised to Bring Innovation in the Market
October 2023, research conducted by Azlaan Ranjha, Laiba Jabbar, Osaid Ahmed focused on creating a wireless, transportable Holter monitor with a specific emphasis on improving cardiac disease diagnosis accuracy. The main goal was to develop a low-cost cardiac screening system tailored for underprivileged areas to address the increasing rates of cardiovascular death. The study demonstrated a deep neural network's superior diagnostic performance, surpassing cardiologist-level ECG analysis with over 88% accuracy. This breakthrough integrates wireless data transfer with cost-effective AI-assisted diagnostics, providing a swift and accurate cardiac screening option.
The development of a wireless, low-cost Holter monitor with advanced AI-assisted diagnostics, achieving over 88% accuracy in cardiac anomaly identification may significantly boost the global Holter ECG market research by providing a more accessible and efficient cardiac screening solution, especially in underprivileged areas.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Lead Type
Market Breakup by Application
Market Breakup by Product
Market Breakup by End User
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America is currently dominating the market due to factors such as the growing incidence of cardiovascular diseases, rising geriatric population, surging demand for remote monitoring, and the proliferation of advanced monitoring devices. The market is further propelled by technological advancements, preference shift towards ambulatory ECG monitoring, the introduction of next-generation wireless monitoring devices, and strategic technological collaborations among manufacturers.
For instance, in May 2023, BIOTRONIK received U.S. Food and Drug Administration (FDA) approval for the BIOMONITOR IV implantable cardiac monitor (ICM), its latest innovation to improve the standard of care in cardiac monitoring. The device, featuring BIOTRONIK’s advanced, AI-powered* SmartECG algorithm, will make its debut at the Heart Rhythm Society Congress 2023 in New Orleans.
BIOMONITOR IV, with SmartECG technology, significantly reduces false atrial fibrillation alerts by 86%, easing the burden on clinicians. It ensures 98% accuracy in detecting true episodes, helping timely and accurate diagnosis. This advancement is likely to boost the Holter ECG market technologies. In addition to the SmartECG technology, BIOMONITOR IV is the first ICM to discriminate between premature atrial contractions (PACs) and premature ventricular contractions (PVCs) marking a significant step forward in the domain of remote cardiac monitoring by providing healthcare professionals with reliable PAC and PVC trends for risk stratification and diagnosis.
The FDA approval for BIOMONITOR IV with advanced SmartECG technology significantly reduces false positive atrial fibrillation detections by 86%, aiding clinicians in accurate diagnoses. Its ability to differentiate between PACs and PVCs, along with enhanced remote monitoring features, is a major factor poised to positively influence the global Holter ECG market growth.
In May 2023, On May 2023, Philips revealed AI research predicting life-threatening ventricular arrhythmias at a Heart Rhythm Society congress. Using a deep neural network and 115,505 ECG recordings, the AI accurately forecasted sustained ventricular tachycardia over two weeks, showcasing potential in cardiac monitoring.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
REPORT FEATURES | DETAILS |
Base Year | 2023 |
Historical Period | 2017-2023 |
Forecast Period | 2024-2032 |
Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
Breakup by Lead Type |
|
Breakup by Application |
|
Breakup by Product |
|
Breakup by End User |
|
Breakup by Region |
|
Market Dynamics |
|
Competitive Landscape |
|
Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Holter ECG Market (2017-2032) Overview
3.1 Global Holter ECG Market (2017-2032) Historical Value (2017-2023)
3.2 Global Holter ECG Market (2017-2032) Forecast Value (2024-2032)
4 Global Holter ECG Market (2017-2032) Landscape*
4.1 Global Holter ECG Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Holter ECG Product Landscape
4.2.1 Analysis by Lead Type
4.2.2 Analysis by Applications
5 Global Interventional Radiology Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.2.1 Strengths
5.2.2 Weaknesses
5.2.3 Opportunities
5.2.4 Threats
5.3 Porter’s Five Forces Model
5.3.1 Bargaining Power of Suppliers
5.3.2 Bargaining Power of Buyers
5.3.3 Threat of New Entrants
5.3.4 Threat of Substitutes
5.3.5 Degree of Rivalry
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Holter ECG Market (2017-2032) Segmentation
6.1 Global Holter ECG Market (2017-2032) by Lead Type
6.1.1 Market Overview
6.1.2 Patch Type Single Monitor
6.1.3 3 Lead Holter Monitors
6.1.4 6 Lead Holter Monitors
6.1.5 12 Lead Holter Monitors
6.1.6 Others
6.2 Global Holter ECG Market (2017-2032) by Application
6.2.1 Market Overview
6.2.2 Diagnostic
6.2.3 Monitoring
6.3 Global Holter ECG Market (2017-2032) by Product
6.3.1 Market Overview
6.3.2 Wired Holter ECG Monitors
6.3.3 Wireless Holter ECG Monitors
6.3.4 Software
6.4 Global Holter ECG Market (2017-2032) by End User
6.4.1 Market Overview
6.4.2 Hospitals and Clinics
6.4.3 Ambulatory Facilities
6.4.4 Others
6.5 Global Holter ECG Market (2017-2032) by Region
6.5.1 Market Overview
6.5.2 North America
6.5.3 Europe
6.5.4 Asia Pacific
6.5.5 Latin America
6.5.6 Middle East and Africa
7 North America Holter ECG Market (2017-2032)
7.1 North America Holter ECG Market (2017-2032) by Lead Type
7.1.1 Market Overview
7.1.2 Patch Type Single Monitor
7.1.3 3 Lead Holter Monitors
7.1.4 6 Lead Holter Monitors
7.1.5 12 Lead Holter Monitors
7.1.6 Others
7.2 North America Holter ECG Market (2017-2032) by Application
7.2.1 Market Overview
7.2.2 Diagnostic
7.2.3 Monitoring
7.3 North America Holter ECG Market (2017-2032) by Country
7.3.1 Market Overview
7.3.2 United States
7.3.3 Canada
8 Europe Holter ECG Market (2017-2032)
8.1 Europe Holter ECG Market (2017-2032) by Lead Type
8.1.1 Market Overview
8.1.2 Patch Type Single Monitor
8.1.3 3 Lead Holter Monitors
8.1.4 6 Lead Holter Monitors
8.1.5 12 Lead Holter Monitors
8.1.6 Others
8.2 Europe Holter ECG Market (2017-2032) by Application
8.2.1 Market Overview
8.2.2 Diagnostic
8.2.3 Monitoring
8.3 Europe Holter ECG Market (2017-2032) by Country
8.3.1 Market Overview
8.3.2 United Kingdom
8.3.3 Germany
8.3.4 France
8.3.5 Italy
8.3.6 Others
9 Asia Pacific Holter ECG Market (2017-2032)
9.1 Asia Pacific Holter ECG Market (2017-2032) by Lead Type
9.1.1 Market Overview
9.1.2 Patch Type Single Monitor
9.1.3 3 Lead Holter Monitors
9.1.4 6 Lead Holter Monitors
9.1.5 12 Lead Holter Monitors
9.1.6 Others
9.2 Asia Pacific Holter ECG Market (2017-2032) by Application
9.2.1 Market Overview
9.2.2 Diagnostic
9.2.3 Monitoring
9.3 Asia Pacific Holter ECG Market (2017-2032) by Country
9.3.1 Market Overview
9.3.2 China
9.3.3 Japan
9.3.4 India
9.3.5 ASEAN
9.3.6 Australia
9.3.7 Others
10 Latin America Holter ECG Market (2017-2032)
10.1 Latin America Holter ECG Market (2017-2032) by Lead Type
10.1.1 Market Overview
10.1.2 Patch Type Single Monitor
10.1.3 3 Lead Holter Monitors
10.1.4 6 Lead Holter Monitors
10.1.5 12 Lead Holter Monitors
10.1.6 Others
10.2 Latin America Holter ECG Market (2017-2032) by Application
10.2.1 Market Overview
10.2.2 Diagnostic
10.2.3 Monitoring
10.3 Latin America Holter ECG Market (2017-2032) by Country
10.3.1 Market Overview
10.3.2 Brazil
10.3.3 Argentina
10.3.4 Mexico
10.3.5 Others
11 Middle East and Africa Holter ECG Market (2017-2032)
11.1 Middle East and Africa Holter ECG Market (2017-2032) by Lead Type
11.1.1 Market Overview
11.1.2 Patch Type Single Monitor
11.1.3 3 Lead Holter Monitors
11.1.4 6 Lead Holter Monitors
11.1.5 12 Lead Holter Monitors
11.1.6 Others
11.2 Middle East and Africa Holter ECG Market (2017-2032) by Application
11.2.1 Market Overview
11.2.2 Diagnostic
11.2.3 Monitoring
11.3 Middle East and Africa Holter ECG Market (2017-2032) by Country
11.3.1 Market Overview
11.3.2 Saudi Arabia
11.3.3 United Arab Emirates
11.3.4 Nigeria
11.3.5 South Africa
11.3.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Patent Analysis
13.1 Analysis by Type of Patent
13.2 Analysis by Publication year
13.3 Analysis by Issuing Authority
13.4 Analysis by Patent Age
13.5 Analysis by CPC Analysis
13.6 Analysis by Patent Valuation
13.7 Analysis by Key Players
14 Grants Analysis
14.1 Analysis by Year
14.2 Analysis by Amount Awarded
14.3 Analysis by Issuing Authority
14.4 Analysis by Grant Application
14.5 Analysis by Funding Institute
14.6 Analysis by NIH Departments
14.7 Analysis by Recipient Organization
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 GE Healthcare
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 Philips Healthcare
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certification
17.3 Medtronic plc
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Schiller AG
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Welch Allyn (now part of Hillrom)
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 BioTelemetry, Inc. (now part of Philips)
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 Spacelabs Healthcare (a subsidiary of OSI Systems, Inc.)
17.7.1 Financial Analysis
17.7.2 Product Portfolio
17.7.3 Demographic Reach and Achievements
17.7.4 Mergers and Acquisitions
17.7.5 Certifications
17.8 Nihon Kohden Corporation
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certification
17.9 ScottCare Corporation (a subsidiary of Biotronik)
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 iRhythm Technologies, Inc.
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
17.11 Cardionet (a subsidiary of BioTelemetry, Inc.)
17.11.1 Financial Analysis
17.11.2 Product Portfolio
17.11.3 Demographic Reach and Achievements
17.11.4 Mergers and Acquisitions
17.11.5 Certifications
17.12 Applied Cardiac Systems, Inc.
17.12.1 Financial Analysis
17.12.2 Product Portfolio
17.12.3 Demographic Reach and Achievements
17.12.4 Mergers and Acquisitions
17.12.5 Certifications
17.13 Compumed Inc.
17.13.1 Financial Analysis
17.13.2 Product Portfolio
17.13.3 Demographic Reach and Achievements
17.13.4 Mergers and Acquisitions
17.13.5 Certifications
17.14 Scott Medical Products (a subsidiary of Cardinal Health)
17.14.1 Financial Analysis
17.14.2 Product Portfolio
17.14.3 Demographic Reach and Achievements
17.14.4 Mergers and Acquisitions
17.14.5 Certification
17.15 Midmark Corporation
17.15.1 Financial Analysis
17.15.2 Product Portfolio
17.15.3 Demographic Reach and Achievements
17.15.4 Mergers and Acquisitions
17.15.5 Certifications
List not exhaustive
18 Holter ECG Market (2017-2032) - Distribution Model (Additional Insight)
18.1 Overview
18.2 Potential Distributors
18.3 Key Parameters for Distribution Partner Assessment
19 Key Opinion Leaders (KOL) Insights (Additional Insight)
20 Company Competitiveness Analysis (Additional Insight)
20.1 Very Small Companies
20.2 Small Companies
20.3 Mid-Sized Companies
20.4 Large Companies
20.5 Very Large Companies
21 Payment Methods (Additional Insight)
21.1 Government Funded
21.2 Private Insurance
21.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
The market attained a value of about USD 543.3 million in 2023, driven by the rising prevalence of CVD.
The market is anticipated to grow at a CAGR of 7.6% during the forecast period of 2024-2032 and is likely to reach a market value of USD 1053.9 million by 2032.
Factors including the rising demand for 12-lead Holter ECG, increasing prevalence of cardiovascular diseases, rising preference for Holter ECG due to its portability and non-interference with routine activities, FDA approvals, research activities, and product launches are major factors aiding the market demand.
Market players launching new technologies such as Abbott’s Assert-IQ™ insertable cardiac monitor (ICM) is a major trend influencing market growth.
The major regions of the market include North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America is currently leading the global market.
Types include patch type single monitors, 3 lead Holter monitors, 6 lead Holter monitors, and 12 lead Holter monitors, among others.
Holter ECG can be used in diagnostics and monitoring.
Types of products available in the market include wired Holter ECG monitors, wireless Holter ECG monitors, and software.
End users in the market are Holter ECG clinic and ambulatory facilities, among others.
Key players involved in the market are GE Healthcare, Philips Healthcare, Medtronic plc, Schiller AG, Welch Allyn (now part of Hillrom), BioTelemetry, Inc. (now part of Philips), Spacelabs Healthcare (a subsidiary of OSI Systems, Inc.), Nihon Kohden Corporation, ScottCare Corporation (a subsidiary of Biotronik), iRhythm Technologies, Inc., Cardionet (a subsidiary of BioTelemetry, Inc.), Applied Cardiac Systems, Inc., Compumed Inc., Scott Medical Products (a subsidiary of Cardinal Health), and Midmark Corporation.
Mini Report
Single User License
Five User License
Corporate License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.